Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 16, 2020
Principal Office: Haifa, Israel
Exchange: The Nasdaq Capital Market
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a new financing arrangement.
- Proposed Offering Size: Up to $75 million in aggregate offering price.
- Agent Commission: Up to 3.0% of gross proceeds.
- Registration Status: Filed on Form S-3 (File No. 333-239890) but not yet declared effective by the SEC.
Material Changes
On July 16, 2020, the company entered into an Open Market Sale Agreement (SM) with Jefferies LLC. This agreement authorizes the company to issue and sell shares of its common stock through an "at-the-market" offering. No shares have been sold under this agreement as of the filing date, and the company is not obligated to make any sales.
Guidance, Outlook, and Risks
Management Commentary: The company retains discretion over the timing, price, and size of any sales. Jefferies will use commercially reasonable efforts to sell shares based on the company's instructions.
Risks and Contingencies:
- Effectiveness: The Registration Statement must be declared effective by the SEC before any sales can occur.
- Uncertainty: There is no assurance that any shares will be sold, nor regarding the price or number of shares if sales occur.
- Termination: Either party may terminate the Sale Agreement as set forth in the contract terms.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement (File No. 333-239890) on the SEC EDGAR database.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses and indemnification rights.
- Monitor future 8-K filings for actual sales activity and proceeds generated under this agreement.
- Check the company's most recent 10-Q or 10-K for current liquidity and cash position to assess the necessity of this potential capital raise.